ReviewFrontiers in immunology2026
Sex differences in innate immune cell responses: Impact on cancer immunity and response to therapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sex hormones regulate innate and adaptive immune responses to infection, autoimmunity, and carcinogenesis through genomic and non-genomic mechanisms. Estrogen, progesterone, and androgen receptors are widely expressed on immune cells and modulate their functional responses to pathological insults. While the impact of biological sex on infection, autoimmunity, and cancer risk has long been appreciated, their impact on response to cancer therapy is only beginning to be explored. Combinatorial strategies are being leveraged in the clinic to elicit antitumor immune responses, but the role of sex and hormones remains underexplored. Given that hormones impact both innate and adaptive immune responses, their interplay within the overall treatment regimen needs to be better understood, particularly for younger patients whose hormone levels remain relatively high, and for aging patients whose immune system divergence evolves despite reduced hormone levels. Herein, we review the interaction between hormones and the innate immune system and its implications for anti-cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.